Hong Kong food distributor Billion Group (BGHL.US) IPO priced at $4-5 per share, raising 111% to $17 million.
Hong Kong high-end food distributor Yifutong Group re-submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) on Tuesday.
High-end food distributor BillionRich Group (BGHL.US), headquartered in Hong Kong, refiled its initial public offering (IPO) application with the U.S. Securities and Exchange Commission (SEC) on Tuesday. According to the latest proposal, the Hong Kong company plans to issue 3.8 million shares of stock, with a price range of $4 to $5 per share, aiming to raise $17 million through this IPO. It is worth noting that BillionRich Group had originally submitted a U.S. listing application in August 2025, but voluntarily withdrew it last Friday. The original plan was to issue 1.6 million shares of stock, with a price range of $4 to $6 per share. Calculated according to the revised terms of issuance, BillionRich Group's fundraising size will increase by 111% compared to the original plan, and the company's estimated valuation is expected to reach $100 million.
With the revised terms of issuance, BillionRich Group will meet Nasdaq's new listing requirements and be able to conduct an IPO in the United States. The new requirements include a minimum public float value of $15 million.
As a high-end food supplier, the company mainly provides high-quality and scarce products to Hong Kong foodservice distributors and luxury retail channels. In its product portfolio, frozen foods account for 60% (represents 24% of fiscal year revenue, the same below), premium wines and spirits account for 24%, high-end seafood accounts for 15%, and other foods account for 1%.
BillionRich Group was founded in 2015 and recorded revenue of $10 million in the 12 months ending December 31, 2025. The company plans to list on Nasdaq under the ticker symbol BGHL. American Trust Investment Services is the sole bookrunner for this transaction.
Related Articles

INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.

CMGE(00302) releases annual performance, with a loss of 1.477 billion yuan, a year-on-year decrease of 30.02%.

JIANGSU EXPRESS (00177) has announced its performance for 2025, with a net profit attributable to shareholders of approximately RMB 4.594 billion, representing a year-on-year decrease of about 7.13%.
INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.

CMGE(00302) releases annual performance, with a loss of 1.477 billion yuan, a year-on-year decrease of 30.02%.

JIANGSU EXPRESS (00177) has announced its performance for 2025, with a net profit attributable to shareholders of approximately RMB 4.594 billion, representing a year-on-year decrease of about 7.13%.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


